Xaira Unveils X-Design: Preclinical Lead in 7 Weeks and a Functional Antibody Against a Tough GPCR
BoWang87 · x · 2026-10-05
Bo Wang of Xaira Therapeutics introduces X-Design, the company's protein-design platform, with results from two active drug programs:
- On an oncology target, just 7 weeks from DNA synthesis to a preclinical lead, with epitope and reagents already prepared.
- A functional antibody antagonist against a challenging GPCR where both conventional library screening and llama immunization had failed.
Wang stresses the bar goes well beyond binding: antibodies must be human-like, functional, cross-reactive across species, and developable — all in the same molecule. These designs were tested in the lab and met real program requirements.
Related event: Xaira Unveils X-Design, De Novo Antibody Design Model(2 posts)→
More from Apps
- Perplexity brings AI teammates to iOS and Android, callable from mobile app — _andychung · 2026-11-20
- OpenAI engineer points to ChatGPT macOS global dictation — but it only works inside the app — athyuttamre · 2026-11-20
- Backdoor matches job seekers with startups: 26K users, 58% hear back within two weeks, free — itsOmSarraf_ · 2026-11-20
- TwitchCon demo: agents edit stream highlights and build games with chat live — paw_lean · 2026-11-20
- R3 Code: A Native Rust Mac Client That Runs All Your Coding Agents — jasonkneen · 2026-11-20
- Dev builds free tool to visualize ChatGPT and Claude AI-search decision paths for brands — UptownOnion · 2026-11-20